Molecular mechanisms of cetuximab resistance in metastatic colorectal cancer

doi:10.3760/cma.j.cn371439-20200208-00025

Abstract

Abstract:

Cetuximab has become an important molecular targeted drug for the treatment of metastatic colorectal cancer (mCRC), which increases the curative effect of chemotherapy and prolongs the survival time. However, some patients develop insensitiveness or resistance to cetuximab, while the complicated molecular mechanisms are not quite clear. With the deep research in epidermal growth factor receptor (EGFR) signaling pathway, the genetic alteration of KRAS, BRAF, PTEN and PIK3CA and polymorphism of microRNA (miRNA) have been proved to associated with cetuximab resistance. Wnt signaling pathway with its negative regulator RNF43 is also considered to be related with cetuximab resistance in recent studies. The review of the progress on molecular mechanisms of cetuximab resistance in mCRC can establish theoretical basis for finding out reasonable drugs to overcome the resistance.

Key words: Colorectal neoplasms, Molecular targeted therapy, Molecular biology, Drug resistance, Molecular mechanism

Su Hao, Liu Wenjie, Bao Mandula, Luo Shou, Wang Xuewei, Zhao Chuanduo, Liu Qian, Wang Xishan, Zhou Zhixiang, Zhou Haitao. Molecular mechanisms of cetuximab resistance in metastatic colorectal cancer[J]. Journal of International Oncology, 2020, 47(5): 308-311.

References 30

[1]	Kirstein MM, Lange A, Prenzler A, et al. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data[J]. Oncologist, 2014,19(11):1156-1168. DOI: 10.1634/theoncologist.2014-0032. doi: 10.1634/theoncologist.2014-0032
[2]	李敏敏, 毕祥, 王哲海. 转移性结直肠癌抗EGFR单抗获得性耐药的研究进展[J]. 国际肿瘤学杂志, 2014,41(5):357-360. DOI: 10.3760/cma.j.issn.1673-422X.2014.05.012. doi: 10.3760/cma.j.issn.1673-422X.2014.05.012
[3]	Sotelo MJ, García-Paredes B, Aguado C, et al. Role of cetuximab in first-line treatment of metastatic colorectal cancer[J]. World J Gastroenterol, 2014,20(15):4208-4219. DOI: 10.3748/wjg.v20.i15.4208. doi: 10.3748/wjg.v20.i15.4208 pmid: 24764659
[4]	刘晓娜, 田庄, 魏晓飞, 等. 联合检测结直肠癌患者血浆及组织中KRAS、NRAS、BRAF及PIK3CA基因突变情况[J]. 中华病理学杂志, 2019,48(5):373-377. DOI: 10.3760/cma.j.issn.0529-5807.2019.05.008.
[5]	Limbach C, Laue MM, Wang X, et al. Molecular in situ topology of Aczonin/Piccolo and associated proteins at the mammalian neurotransmitter release site[J]. Proc Natl Acad Sci U S A, 2011,108(31):E392-E401. DOI: 10.1073/pnas.1101707108. doi: 10.1073/pnas.1101707108 pmid: 21712437
[6]	Douillard JY, Siena S, Cassidy J, et al. Randomized, phase Ⅲ trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study[J]. J Clin Oncol, 2010,28(31):4697-4705. DOI: 10.1200/JCO.2009.27.4860. doi: 10.1200/JCO.2009.27.4860 pmid: 20921465
[7]	Dienstmann R, De Dosso S, Felip E, et al. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer[J]. Mol Oncol, 2012,6(1):15-26. DOI: 10.1016/j.molonc.2011.11.009. doi: 10.1016/j.molonc.2011.11.009
[8]	Clark JI, Singh J, Ernstoff MS, et al. A multi-center phase Ⅱ study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma[J]. J Immuno-ther Cancer, 2018,6(1):76. DOI: 10.1186/s40425-018-0387-x.
[9]	Van Cutsem E, Kohne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colo-rectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status[J]. J Clin Oncol, 2011,29(15):2011-2019. DOI: 10.1200/JCO.2010.33.5091. doi: 10.1200/JCO.2010.33.5091
[10]	Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer[J]. J Clin Oncol, 2011,29(10):1261-1270. DOI: 10.1200/JCO.2010.30.1366. doi: 10.1200/JCO.2010.30.1366
[11]	Yuan ZX, Wang XY, Qin QY, et al. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis[J]. PLoS One, 2013,8(6):e65995. DOI: 10.1371/journal.pone.0065995. doi: 10.1371/journal.pone.0065995 pmid: 23776587
[12]	Haddadi N, Lin Y, Travis G, et al. PTEN/PTENP1: 'regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy[J]. Mol Cancer, 2018,17(1):37. DOI: 10.1186/s12943-018-0803-3. doi: 10.1186/s12943-018-0803-3 pmid: 29455665
[13]	Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients[J]. Br J Cancer, 2007,97(8):1139-1145. DOI: 10.1038/sj.bjc.6604009. doi: 10.1038/sj.bjc.6604009 pmid: 17940504
[14]	Razis E, Pentheroudakis G, Rigakos G, et al. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetu-ximab[J]. J Cancer Res Clin Oncol, 2014,140(5):737-748. DOI: 10.1007/s00432-014-1626-2. doi: 10.1007/s00432-014-1626-2 pmid: 24595598
[15]	De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis[J]. Lancet Oncol, 2010,11(8):753-762. DOI: 10.1016/S1470-2045(10)70130-3. doi: 10.1016/S1470-2045(10)70147-9 pmid: 20619739
[16]	Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a micro-RNA expression analysis[J]. Lancet Oncol, 2010,11(2):136-146. DOI: 10.1016/S1470-2045(09)70343-2. doi: 10.1016/S1470-2045(09)70386-9 pmid: 20022810
[17]	Ruzzo A, Graziano F, Vincenzi B, et al. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease[J]. Oncologist, 2012,17(6):823-829. DOI: 10.1634/theoncologist.2012-0081. doi: 10.1634/theoncologist.2012-0081
[18]	Mosakhani N, Lahti L, Borze I, et al. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF[J]. Cancer Genet, 2012,205(11):545-551. DOI: 10.1016/j.cancergen.2012.08.003. doi: 10.1016/j.cancergen.2012.08.003 pmid: 23098991
[19]	Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer[J]. Oncogene, 2017,36(11):1461-1473. DOI: 10.1038/onc.2016.304. doi: 10.1038/onc.2016.304 pmid: 27617575
[20]	Ma Y, Yang Y, Wang F, et al. Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/β-catenin signalling pathway via suppression of activator protein 2α[J]. Gut, 2016,65(9):1494-1504. DOI: 10.1136/gutjnl-2014-308392. doi: 10.1136/gutjnl-2014-308392 pmid: 25994219
[21]	Hu T, Li C. Convergence between Wnt-β-catenin and EGFR signaling in cancer[J]. Mol Cancer, 2010,9(1):236. DOI: 10.1186/1476-4598-9-236. doi: 10.1186/1476-4598-9-236
[22]	Therkildsen C, Bergmann TK, Henrichsen-Schnack T, et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis[J]. Acta Oncol, 2014,53(7):852-864. DOI: 10.3109/0284186X. doi: 10.3109/0284186X.2014.895036
[23]	Koo BK, Spit M, Jordens I, et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors[J]. Nature, 2012,488(7413):665-669. DOI: 10.1038/nature11308. doi: 10.1038/nature11308
[24]	徐星宇, 来茂德. 环指蛋白43的结构、功能及其在肿瘤中的作用[J]. 临床与实验病理学杂志, 2016,32(6):673-677. DOI: 10.13315/j.cnki.cjcep.2016.06.017.
[25]	Serra S, Chetty R. Rnf43[J]. J Clin Pathol, 2018,71(1):1-6. DOI: 10.1136/jclinpath-2017-204763. doi: 10.1136/jclinpath-2017-204763 pmid: 29018044
[26]	Lebensohn AM, Rohatgi R. R-spondins can potentiate WNT signaling without LGRs[J]. Elife, 2018,7:e33126. DOI: 10.7554/eLife.33126. doi: 10.7554/eLife.33126 pmid: 29405118
[27]	Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer[J]. Cancer Cell, 2018,33(1): 125-136.e3. DOI: 10.1016/j.ccell.2017.12.004. doi: 10.1016/j.ccell.2017.12.004 pmid: 29316426
[28]	Steinhart Z, Pavlovic Z, Chandrashekhar M, et al. Corrigendum: Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors[J]. Nat Med, 2017,23(11):1384. DOI: 10.1038/nm1117-1384d. doi: 10.1038/nm1117-1384d pmid: 29117169
[29]	Coffey RJ, Hawkey CJ, Damstrup L, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells[J]. Proc Natl Acad Sci U S A, 1997,94(2):657-662. DOI: 10.1073/pnas.94.2.657. doi: 10.1073/pnas.94.2.657 pmid: 9012840
[30]	Lu Y, Zhao X, Liu Q, et al. lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling[J]. Nat Med, 2017,23(11):1331. DOI: 10.1038/nm.4424. doi: 10.1038/nm.4424 pmid: 29035371